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Primary graft dysfunction (PGD) after lung trans-
plantation causes significant morbidity and mortal-
ity. We aimed to determine the role of cytokines and
chemokines in PGD. This is a multicenter case–control
study of PGD in humans. A Luminex analysis was per-
formed to determine plasma levels of 25 chemokines
and cytokines before and at 6, 24, 48 and 72 h fol-
lowing allograft reperfusion in 25 cases (grade 3 PGD)
and 25 controls (grade 0 PGD). Biomarker profiles
were evaluated using a multivariable logistic regres-
sion and generalized estimating equations. PGD cases
had higher levels of monocyte chemotactic protein-1
(MCP-1)/chemokine CC motif ligand 2 (CCL2) and in-
terferon (IFN)-inducible protein (IP-10)/chemokine CXC
motif ligand 10 (CXCL10) (both p < 0.05), suggesting
recruitment of monocytes and effector T cells in PGD.
In addition, PGD cases had lower levels of interleukin
(IL-13) (p = 0.05) and higher levels of IL-2R (p = 0.05).
Proinflammatory cytokines, including tumor necrosis
factor (TNF)-a, and IFN-c decreased to very low levels
after transplant in both PGD cases and controls, ex-
hibiting no differences between the two groups. These
findings were independent of clinical variables includ-
ing diagnosis in multivariable analyses, but may be
affected by cardiopulmonary bypass. Profound injury
in clinical PGD is distinguished by the upregulation of
selected chemokine pathways, which may useful for
the prediction or early detection of PGD if confirmed in
future studies.
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Introduction
Primary graft dysfunction (PGD) is a form of is-
chemia/reperfusion (I/R) acute lung injury that complicates
an estimated 10–25% of lung transplantations and is the
leading cause of early posttransplantation morbidity and
mortality (1–9). Seen pathologically, there is a predomi-
nance of the diffuse alveolar damage lung injury pattern,
and the pathophysiology is felt to be most likely due to
I/R injury (10–13). Recent studies have implicated a patho-
physiological role for cytokines and chemokines in PGD
or I/R injury, often focusing on small groups of markers
in animal models, lung tissue or bronchoalveolar lavage
(BAL) (5,14,15). Likewise, there is a growing interest in
anti-cytokine and -chemokine therapy in PGD prevention
and therapy (12).
Our goal was to determine the time course of changes
in the systemic expression of selected cytokines and
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chemokines after transplantation in human subjects with
PGD, compared with controls without PGD. To achieve
this, we measured the following categories of media-
tors: (a) proinflammatory cytokines involved in the activa-
tion of lymphocytes and neutrophils, including interleukin
(IL)-1b, IL-2, IL-2 receptor (IL-2R), IL-5, IL-7, IL-12 and tu-
mor necrosis factor (TNF)-a; (b) anti-inflammatory and
pleiotropic cytokines IL-2 receptor antagonist (IL-1Ra),
IL-4, IL-6, IL-10 and IL-13; (c) chemokines involved in the re-
cruitment of neutrophils, IL-8 and (d) chemokines involved
in the recruitment of monocytes and lymphocytes, inter-
feron (IFN)-inducible protein (IP-10), monocyte chemotac-
tic protein-1 (MCP-1), monokine induced by IFN-c (MIG),
macrophage inflammatory protein (MIP-1a) and MIP-1b.
The mediators were measured in plasma samples col-
lected before lung transplantation and at 6, 24, 48 and
72 h following allograft reperfusion.
Methods
Study population
The Lung Transplant Outcomes Group (LTOG) is an ongoing prospective
cohort study of patients undergoing first lung transplantation at nine cen-
ters in the United States, designed to study the risks and pathogenesis
of PGD (see Appendix for institutions and investigators). Subjects in this
cohort study underwent postoperative immunosuppression, according to
local protocols, that included induction with IL-2Ra, followed by mainte-
nance with a calcineurin inhibitor, azathioprine or mycophenolate mofetil,
and steroids.
We performed a case–control study nested within the LTOG cohort. We
chose the nested case–control study approach using our most severe cases
of PGD (grade 3, at 72 h after transplantation [T72]) and our ‘cleanest’ non-
PGD controls (grade 0 at all time points) to best uncover the differences
in biomarkers between the ends of the spectrum of PGD, as well as for
efficiency due to the high cost of these multiple assays (16). Because of
the high cost of the assay platform, we sought to maximize the efficiency
by choosing a nested sample of 25 cases and 25 controls. Specifically, 25
cases were selected from the first 128 lung transplant recipients enrolled
between April 2002 and November 2005 (17). PGD cases met the criteria for
International Society of Heart and Lung Transplantation (ISHLT) grade 3 PGD
defined at 72 h after transplantation, as defined in prior studies (1,2,6,10).
The cases had (a) diffuse alveolar infiltrates involving the lung allograft(s)
(in the case of single lung transplant, infiltrates spare the native lung), (b)
PaO2/FiO2 less than 200 mmHg and (c) no other secondary cause of graft
dysfunction identified. In previous studies, PGD defined by these criteria
was associated with poor outcomes after lung transplantation including an
increased risk of death (1,2,6).
From the same time period, 25 controls were chosen, characterized by
ISHLT grade 0 PGD defined at 72 h after lung transplantation. Matching
of controls was not performed on clinical variables to avoid errors due to
overmatching (16).
Data collection and management
Informed consent for this study was obtained prior to organ transplantation.
Blood samples were obtained in citrated Vacutainers (Becton Dickinson,
Franklin Lakes, NJ) from the recipients immediately before transplantation
and at 6, 24, 48 and 72 h after reperfusion of the lung allograft(s). The
samples were centrifuged within 30 min of collection and stored at –80◦C.
Clinical variables were categorized and defined using methods published
previously (3,17). Some patients from this study have been included in other
studies of biomarkers of coagulation and endothelial injury in PGD (17,18).
Multiplex analysis of plasma chemokines and cytokines
The levels of 25 cytokines and chemokines in 25 lL of plasma were as-
sayed simultaneously, in duplicate, using a human cytokine 25-plex antibody
bead kit (BioSource, Camarillo, CA) and a Luminex-100 array assay reader
(Luminex Corp., Austin, TX). The analytes were IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin, IFN)-c -inducible protein (IP)-10,
MIG, MCP-1, MIP-1a, MIP-1b, Regulated upon Activation, Normal T-cell Ex-
pressed (RANTES), also known as CCL5, TNF-a, IFN-a, IFN-c , granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-1Ra and IL-2R.
Statistical analysis
The continuous variables were compared between the cases and controls
using t-tests and rank-sum tests. Generalized estimating equations (GEE),
a statistical tool to test the relationships of longitudinal variables between
groups, were used to assess the differences in biomarker profiles over time
between PGD cases and non-PGD controls. To assess the potential con-
founding effects of imbalances in clinical variables between the groups, a
multivariable logistic regression was used for biomarker levels at the 24-h
time point. For each mediator analyzed in multivariable analyses, the cutoffs
were chosen based on the median levels. The confounders were included
one at a time in adjusted models if p < 0.20 in bivariable analyses. Be-
cause of the potential confounding effect of diagnosis category, in addition
to adjusting, we performed analyses excluding individuals with a given di-
agnosis (such as idiopathic pulmonary fibrosis [IPF] or idiopathic pulmonary
artery hypertension [IPAH]). With a = 0.05, the study had an 80% power
to detect differences of 0.8 standard deviations (SD) for mediators at each
time point. Statistical comparisons were performed using STATA version
9.1 (STATA Corp., College Station, TX) and SAS version 9.1 (SAS Institute,
Cary, NC). This research protocol was approved by the institutional review
board at each participating center.
Results
The characteristics of the study population are shown in
Table 1. Subjects in the PGD group had higher preoperative
pulmonary artery systolic pressures and more frequent
use of cardiopulmonary bypass during transplantation and
were more likely to have a diagnosis of diffuse parenchymal
lung disease or idiopathic pulmonary arterial hypertension.
Ages, ischemic times and the use of medications were
similar between groups.
Chemokines
The largest differences between PGD and non-PGD were
observed for two chemokines, MCP-1 and IP-10. As seen
in Figure 1A, MCP-1 levels appeared higher preopera-
tively, and remained higher in PGD subjects throughout the
period of observation (p = 0.005). There were no associ-
ations between MCP-1 levels and preoperative diagnosis
or elevated pulmonary arterial pressures. A multivariable
explanatory logistic regression model for the relationship
of higher MCP-1 at 24 h with PGD revealed no confound-
ing by diagnosis category, age, sex or other demographic
variables (Table 3). Notably, when IPAH or diffuse parenchy-
mal lung disease (DPLD) were excluded from the analyses,
higher MCP-1 levels remained associated with PGD. How-
ever, this relationship was slightly attenuated by both the
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Table 1: Donor and recipient characteristics by PGD status, with
continuous variables expressed as means with 95% confidence
intervals, and dichotomous variables as column percentages
No PGD PGD
Donor variable (n = 25) (n = 25) p-Value
Mean donor age in
years (95% CI)
30 (24–36) 33 (27–39) 0.44
Female gender 28% 46% 0.20
Race/ethnicity 0.53
Caucasian 70% 65%
African American 17% 9%
Hispanic 13% 22%
Other 0% 4%





Age, years 53 (46–60) 42 (32–52) 0.07
Female gender 40% 36% 0.77
Race/ethnicity 0.27
Caucasian 92% 72%

































39 (33–44) 68 (53–83) <0.001
Ischemic time in minutes
First lung 232 (211–253) 241 (224–259) 0.50
Second lung 345 (318–373) 344 (281–406) 0.96
degree of elevated right heart pressures and the use of
cardiopulmonary bypass.
The two related chemokines IP-10 (p = 0.02) and MIG (p =
0.07) were similar preoperatively, then diverged postopera-
tively between PGD cases and non-PGD controls, peaking
at 24 h postoperatively in PGD cases, then dropping to
control levels at later time points (Figure 1B and C). Al-
though the MIG profile did not achieve overall statistical
significance, early postoperative time points diverged. In
Table 2: Detection limits and percentages of total assays with
values at lower limits of detection
Percentage of assays
Lower limit of with levels at lower


























the multivariable analyses, IP-10 levels at 24 h remained
associated with PGD, independent of the potential con-
founding effects of clinical variables (Table 3), including the
use of cardiopulmonary bypass, right heart pressures and
diagnostic categories. Furthermore, when patients from
an unbalanced diagnostic group (such as DPLD) were ex-
cluded from the analyses, the results remained significant.
Chemokines that did not have statistically significant
differences at any time points included IL-8, eotaxin,
MIP-1a, MIP-1b and RANTES. Preoperative IL-8 plasma
levels were widely variable in PGD cases and consistently
low in controls, with plasma levels becoming low in both
groups postoperatively (Figure 1D). However, we found no
association of preoperative IL-8 levels with diagnosis cat-
egory, hemodynamic variables or recipient demographic
variables.
Cytokines and their receptors
Similar to the chemokines, cytokines and/or their receptors
had varying changes in plasma levels over time (Figures 2
and 3). Cytokine levels that differed between the cases
and controls included IL-2R (p = 0.05), with PGD case sub-
ject levels consistently greater than control subject levels
(Figure 2A). Plasma levels diverged at later time points be-
tween PGD cases and controls for IL-6 (p < 0.05 at 48
and 72 h) and IL-13 (p < 0.05 at 72 h) (Figure 2C and D),
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Figure 1: Mean plasma
levels (pg/mL) of chemo-
kines in PGD cases and con-
trols. (A) MCP-1. (B) IP-10.
(C) MIG. (D) IL-8. Standard
errors are shown as error
bars, and the GEE p-value is
displayed. Asterisks signify
significant differences at time
points between PGD case
and control plasma levels
(p < 0.05).
although the overall profile p-values did not reach signifi-
cance for these mediators.
A number of cytokines showed marked reductions in post-
operative plasma levels, and did not differ between PGD
cases and controls, including IL-2, IL-4, IL-5, IL-7, IL-10,
IL-12, IL-15 and IL-17. Notably, as illustrated in Figure 3A
and B, TNF-a and IL-1b levels likewise fell precipitously in
the postoperative period in both cases and controls.
Interferons
The IFNs exhibited patterns similar to inflammatory cy-
tokines (Figure 3C and D). IFN-a plasma levels initially
Table 3: Multivariable analysis of association of MCP-1 and IP-10 levels at 24 h with PGD
MCP-1 >200 pg/mL IP-10 >50 pg/mL
Variable Odds ratio (95% CI) p-Value Odds ratio (95% CI) p-Value
Unadjusted base model 5.3 (1.4–19.5) 0.013 14.7 (3.0–73.0) 0.001
Adjusted for
Donor gender 4.9 (1.3–18.9) 0.023 12.8 (2.5–65.3) 0.002
Recipient age 4.7 (1.2–18.0) 0.024 14.7 (2.8–76.2) 0.001
Procedure type 4.6 (1.2–17.7) 0.025 18.9 (3.2–111.5) 0.001
Cardiopulmonary bypass 3.5 (0.8–15.8) 0.109 8.3 (1.5–46.8) 0.017
Total Ischemic time 4.4 (1.1–17.3) 0.035 15.7 (2.9–84.5) 0.001
Pulmonary artery systolic pressure at transplant 4.3 (0.82–22.8) 0.084 9.8 (1.6–58.7) 0.012
Recipient diagnosis 8.2 (1.4–49.7) 0.022 9.2 (1.7–50.3) 0.011
Excluding subjects with DPLD 5.5 (1.3–22.7) 0.019 14.7 (2.7–78.9) 0.002
Excluding subjects with CF 8.4 (1.4–49.9) 0.020 10.5 (1.5–73.4) 0.018
Excluding subjects with IPAH 4.0 (1.1–15.5) 0.041 12.5 (2.5–63.0) 0.002
The reported odds ratios are for the relationship between change in each biomarker and PGD risk, adjusted individually for each confounder
variable listed in the table. Odds ratios for MCP-1 and IP-10 are reported for cutoff values of 200 pg/mL and 50 pg/mL, respectively.
dropped postoperatively in both groups, but at 24 h post-
operatively and beyond, PGD cases had lower levels than
controls (p < 0.05 at 24, 48, and 72 h).
Discussion
We evaluated the relationship of plasma cytokines and
chemokines with PGD after lung transplantation. Build-
ing on previous laboratory investigations, our study is the
first to simultaneously measure a comprehensive panel
of immune-modulating mediators in the plasma of human
lung transplant recipients at numerous perioperative time
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Figure 2: Mean plasma
levels (pg/mL) of cy-
tokines in PGD cases
and controls. (A) IL-2R.
(B) IL-1ra. (C) IL-13. (D) IL-6.
Standard errors are shown
as error bars, and the
GEE p-value is displayed.
Asterisks signify significant
differences at time points
between PGD case and
control plasma levels (p <
0.05).
points. Several interesting observations arise from this in-
vestigation, particularly regarding the large differences in
plasma MCP-1 and IP-10 levels between PGD cases and
controls as well as the lack of difference in proinflammatory
cytokine response in plasma. Furthermore, we showed
that associations of MCP-1 and IP-10 with PGD were in-
dependent of preoperative clinical factors, and that higher
Figure 3: Mean plasma lev-
els (pg/mL) of inflamma-
tory cytokines and interfer-
ons in PGD cases and con-
trols. (A) IL-1b. (B) TNF-a. (C)
INF-a. (D) IFN-c . Standard er-
rors are shown as error bars,
and the GEE p-value is dis-
played. Asterisks signify sig-
nificant differences at time
points between PGD case
and control plasma levels (p
< 0.05).
MCP-1 levels were related to the use of cardiopulmonary
bypass.
Importantly, we demonstrated that the associations of
MCP-1 and IP-10 with PGD were independent of the differ-
ences in preoperative clinical variables, including diagnosis
categories. Confounding effects of clinical variables can be
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addressed using several methods in human studies, includ-
ing matching, adjustment in multivariable regression mod-
els and exclusion of categories that are imbalanced. We
did not performing upfront matching, since this strategy
may lead to errors due to overmatching (16). Instead, we
demonstrated that chemokine associations were robust
when confounding clinical variables were included in mul-
tivariable logistic regression models as well as when we ex-
cluded subjects with diagnoses that appeared imbalanced
between the groups (such as DPLD or IPAH). However, we
were unable to definitively determine whether MCP-1 was
simply higher concurrent with cardiopulmonary bypass use
due to pulmonary arterial hypertension, or whether MCP-1,
elevated right heart pressures and cardiopulmonary bypass
use are part of a causal pathway in PGD pathogenesis. Fu-
ture laboratory and clinical studies may address this issue.
MCP-1 and IP-10 are implicated in myocardial I/R injury (19),
and clinical (20,21) and experimental (22,23) data show that
IP-10 plays a key role in early injury after cardiac and kid-
ney transplantation. Elevated postoperative levels of each
of the observed chemokines may simply be an epiphe-
nomenon of lung injury, or else be part of the causal path-
way in PGD pathogenesis. Potential explanations for ele-
vated levels of IP-10, MCP-1 and MIG include: (a) higher IFN
production in response to injury, (b) increased sensitivity
to IFN production in PGD cases and/or (c) overproduction
of these mediators despite normal tissue IFN levels and
sensitivity. Regardless, the findings suggest that PGD risk
reduction may potentially be achieved via modulation of
the chemokine CC motif receptor 2 (CCR2) and chemokine
CXC motif receptor 3 (CXCR3) receptors. Additional studies
in animal models may help further unravel these associa-
tions and identify key points for a rational therapy. Further-
more, our findings suggest that these mediators may be
useful in the future for the prediction or early recognition
of PGD. However, future studies of clinical utility of these
biomarkers will require validation and will need to include
the entire spectrum of PGD.
One of the striking findings of our investigation was a
marked reduction in both case and control plasma levels
of multiple proinflammatory mediators, including (but not
limited to) TNF-a, IL-1b and IL-2. There are three potential
explanations for this global trend in our study. First, an early
proinflammatory response may not have been captured by
study blood drawing time points, particularly prior to 6 h
postoperatively. In human lung transplantation, lung tissue
levels of TNF-a, IFN-c and IL-8 elevate during the ischemic
time, and subsequently decrease within 2 h of reperfusion
(5); after 24 h posttransplantation, there are no noticeable
elevations in plasma levels of TNF-a (24). Second, reduc-
tion in plasma proinflammatory mediators may be due to
a postoperative suppression of NF-jB-mediated transcrip-
tion, as seen in a canine lung allograft model, despite tem-
porary elevations in these cytokines in the BAL (14). Lastly,
these mediators may have bound to soluble receptors in
the plasma, reducing measured plasma levels.
Our study has several limitations. First, although our study
had adequate power to detect moderate differences be-
tween mediators, the sample size may be too low to detect
subtle differences, or to detect differences where there is a
large variance. Therefore, negative results should be inter-
preted with caution. Second, the case and control groups
had differences in clinical variables, including diagnoses
and pulmonary hypertension. However, the multivariable
analyses performed revealed little effects of diagnosis cat-
egory on the relationship of mediators with PGD. Third,
since we assessed multiple biomarkers, it is possible that
some of our differences are false-positive results. How-
ever, since each of our mediators was assessed at multi-
ple time points, statistical significance can be interpreted
in the setting of consistency with other time points within
the same individual, strengthening the confidence that the
results are not just ‘random noise’. Fourth, we did not have
access to validly collected donor samples; therefore, future
studies will need to focus on donors. Fifth, we chose to an-
alyze the extremes of the PGD spectrum grade 0 and grade
3, given the high cost of the assay platform. Future studies
will need to focus on other PGD grades. Sixth, many of our
mediators had levels at or below the detection limits of the
assays (Table 2). Therefore, our negative results should be
interpreted with caution. Finally, BAL samples were not
available, and correlations between plasma and lung com-
partments cannot be made. Our findings therefore suggest
the importance of these data for directing future scien-
tific inquiry, both clinical and basic, including future stud-
ies of the clinical utility of these biomarkers in predicting
PGD.
In conclusion, this study provides useful data on early
plasma levels of multiple cytokines and chemokines from
a well-characterized cohort undergoing lung transplanta-
tion. In subjects developing PGD, there was an increase
in plasma levels of MCP-1 and IP-10, suggesting an IFN-
induced activation of macrophages, endothelium and ep-
ithelium in these subjects and attraction of monocytes (via
CCR2) and effector T cells (via CXCR3). These findings
suggest promising targets for further investigation as me-
diators of lung injury as well as potential clinical biomarkers
for the prediction or early recognition of PGD.
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